A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Metastatic Castration Resistant Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • GenesisCare North Shore (Oncology), Sydney, New South Wales, Australia

    Contact: Principal Investigator (Ganessan Kichenadasse)
  • Sydney Adventist Hospital, Sydney, New South Wales, Australia

    Contact: Principal Investigator (Gavin Marx, Prof)
  • Cancer Research SA, Adelaide, South Australia, Australia

    Contact: Study coordinator (Sarwan Bishnoi)
    Contact: Principal Investigator (Sarwan Bishnoi)
  • Southern Oncology Clinical Research Unit, Adelaide, South Australia, Australia

    Contact: Principal Investigator (Ganessan Kichenadasse)
  • Icon Cancer Centre South Brisbane, Brisbane, Australia

    Contact: Principal Investigator (Jermaine Coward, Dr)
  • John Flynn Private Hospital, Brisbane, Australia

    Contact: Principal Investigator (David Martin, Dr)
  • Eastern Health (Box Hill Hospital), Melbourne, Australia

    Contact: Principal Investigator (Ian Davis)
  • Linear Clinical Research Ltd, Perth, Australia

    Contact: Principal Investigator (Timothy Humphries, Dr)
  • Macquarie University, Sydney, Australia

    Contact: Principal Investigator (Howard Gurney)
  • MUPharm Pty Limited trading as Macquarie University Hospital Pharmacy, Sydney, Australia

    Contact: Study coordinator (Jane Stidworthy)
    Contact: Principal Investigator (Howard Gurney)
  • Illawarra Shoalhaven Local Health District (Wollongong Hospital), Wollongong, Australia

    Contact: Principal Investigator (Gary Tincknell, Dr)